Table 1B.
Seroconversion (neutralising antibodies) of CD1 mice after immunisation with candidate SARS-CoV vaccine
| Vaccine group | Vaccine dose (μg) |
|||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 0.2 | 0.04 | 0.008 | 0.0016 | 0.0003 | Control | E.D.50 (ng) | |
| Number of seroconvertersa/number of animals tested (week 5) | ||||||||
| w/o adjuvant | n.d. | 4/4 | 4/4 | 4/4 | 0/4 | 0/4 | 0/4 | 3.6 |
| 0.05% alum | n.d. | 4/4 | 2/4 | 3/4 | 1/4 | 0/4 | 0/4 | 8 |
| Number of seroconvertersa/number of animals tested (week 13) | ||||||||
| 0.2% alum | n.d. | 4/4 | 4/4 | 4/4 | 2/4 | 0/4 | 0/4 | 1.6 |
a
Mice that developed neutralising antibodies were rated as seroconverters; n.d.: not done.